Yancheva Nina, Tzonev Radin
1 Department of AIDS, Specialized Hospital for Active Treatment of Infectious and Parasitic Diseases "Prof. Iv. Kirov" Medical University, Sofia, Bulgaria.
2 Department of Gastroenterology, Tokuda Acibadem Hospital, Sofia, Bulgaria.
Int J STD AIDS. 2019 May;30(6):620-622. doi: 10.1177/0956462419826723. Epub 2019 Feb 5.
We report a case of darunavir-induced cholestatic hepatitis in a human immunodeficiency virus (HIV)-infected patient in the third year of his combined antiretroviral therapy. During the patient's monthly follow-up with regard to his HIV infection, elevated transaminase levels were detected. The patient was subsequently hospitalised at the AIDS and gastroenterology departments. All tested viral hepatitis markers were negative. A diagnosis of autoimmune hepatitis was also ruled out. The liver biopsy revealed cholestatic hepatitis. Darunavir withdrawal resulted in a progressive decrease in liver enzyme levels. We highlight the importance of recognising late development of liver injury secondary to the use of darunavir, and the importance of monitoring liver function in patients undergoing prolonged treatment involving darunavir.
我们报告了1例在接受抗逆转录病毒联合治疗3年的人类免疫缺陷病毒（HIV）感染患者中，由达芦那韦引起的胆汁淤积性肝炎病例。在该患者每月进行的HIV感染随访中，检测到转氨酶水平升高。该患者随后入住艾滋病科和消化内科。所有检测的病毒性肝炎标志物均为阴性。自身免疫性肝炎的诊断也被排除。肝活检显示为胆汁淤积性肝炎。停用达芦那韦后，肝酶水平逐渐下降。我们强调认识到使用达芦那韦继发肝损伤的晚期发生情况的重要性，以及在接受涉及达芦那韦的长期治疗的患者中监测肝功能的重要性。
